| 6.79 -0.2 (-2.86%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.68 | 1-year : | 10.14 |
| Resists | First : | 7.44 | Second : | 8.68 |
| Pivot price | 6.76  |
|||
| Supports | First : | 6.29 | Second : | 5.59 |
| MAs | MA(5) : | 6.93 |
MA(20) : | 6.61 |
| MA(100) : | 4.97 |
MA(250) : | 3 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.2 |
| %K %D | K(14,3) : | 62 |
D(3) : | 71.4 |
| RSI | RSI(14): 55.6 |
|||
| 52-week | High : | 7.44 | Low : | 0.97 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ZURA ] has closed below upper band by 47.4%. Bollinger Bands are 30.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.05 - 7.08 | 7.08 - 7.11 |
| Low: | 6.47 - 6.51 | 6.51 - 6.54 |
| Close: | 6.74 - 6.79 | 6.79 - 6.84 |
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Thu, 12 Mar 2026
Atika Capital Management LLC Takes Position in Zura Bio Limited $ZURA - MarketBeat
Tue, 10 Mar 2026
Zura Bio Updates Corporate Outlook on Lead Tibulizumab Program - TipRanks
Tue, 10 Mar 2026
Zura Bio updates corporate presentation, flags tibulizumab Phase 2 readouts, cash and shares - TradingView
Fri, 06 Mar 2026
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Mon, 02 Mar 2026
Zura Bio to Participate in Upcoming Investor Conferences - mydailyrecord.com
Mon, 02 Mar 2026
Zura Bio to Participate in Upcoming Investor Conferences - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 95 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 23.2 (%) |
| Held by Institutions | 62 (%) |
| Shares Short | 4,080 (K) |
| Shares Short P.Month | 3,010 (K) |
| EPS | -0.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.65 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.3 % |
| Return on Equity (ttm) | -45.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -10.45 |
| PEG Ratio | 0 |
| Price to Book value | 4.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|